BRPI0912234A2 - derivados de salinosporamida como inibidores de proteassomas - Google Patents

derivados de salinosporamida como inibidores de proteassomas

Info

Publication number
BRPI0912234A2
BRPI0912234A2 BRPI0912234A BRPI0912234A BRPI0912234A2 BR PI0912234 A2 BRPI0912234 A2 BR PI0912234A2 BR PI0912234 A BRPI0912234 A BR PI0912234A BR PI0912234 A BRPI0912234 A BR PI0912234A BR PI0912234 A2 BRPI0912234 A2 BR PI0912234A2
Authority
BR
Brazil
Prior art keywords
salinosporamide
derivatives
proteasome inhibitors
proteasome
inhibitors
Prior art date
Application number
BRPI0912234A
Other languages
English (en)
Inventor
Barbara Christine Potts
Katherine A Mcarthur
Rama Rao Manam
Saskia Theodora Cornelia Neuteboom
Ta-Hsiang Chao
Venkat Rami Reddy Macherla
Original Assignee
Nereus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc filed Critical Nereus Pharmaceuticals Inc
Publication of BRPI0912234A2 publication Critical patent/BRPI0912234A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0912234A 2008-05-12 2009-05-12 derivados de salinosporamida como inibidores de proteassomas BRPI0912234A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5257608P 2008-05-12 2008-05-12
PCT/US2009/043644 WO2009140287A1 (en) 2008-05-12 2009-05-12 Salinosporamide derivatives as proteasome inhibitors

Publications (1)

Publication Number Publication Date
BRPI0912234A2 true BRPI0912234A2 (pt) 2015-10-06

Family

ID=41319025

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912234A BRPI0912234A2 (pt) 2008-05-12 2009-05-12 derivados de salinosporamida como inibidores de proteassomas

Country Status (13)

Country Link
US (3) US7910616B2 (pt)
EP (1) EP2276765A4 (pt)
JP (1) JP2011519975A (pt)
KR (1) KR20110011645A (pt)
CN (1) CN102089312A (pt)
AU (1) AU2009246467A1 (pt)
BR (1) BRPI0912234A2 (pt)
CA (1) CA2723465A1 (pt)
CO (1) CO6290654A2 (pt)
IL (1) IL209046A0 (pt)
MX (1) MX2010012341A (pt)
WO (1) WO2009140287A1 (pt)
ZA (1) ZA201008098B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
KR20060026052A (ko) * 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
NZ544858A (en) * 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
MX2007006526A (es) * 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
BRPI0709474A2 (pt) * 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
WO2008137780A2 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
AU2009241635A1 (en) 2008-03-07 2009-11-05 Nereus Pharmaceuticals, Inc. Total synthesis of Salinosporamide A and analogs thereof
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors
CN108135871B (zh) 2015-07-23 2022-11-04 博蔚医药生物科技股份有限公司 阻断疾病的泛素化-蛋白酶体系统的胺萘醌化合物及医药组合物
NZ739185A (en) 2015-07-30 2022-10-28 Calgent Biotechnology Co Ltd Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
US20170348284A1 (en) 2016-06-01 2017-12-07 Celgene Tri A Holdings Ltd. Use of marizomib for the treatment of central nervous system (cns) cancers
WO2018033631A1 (en) 2016-08-19 2018-02-22 Celgene International Ii Sàrl Morphic forms of marizomib and uses thereof
KR101953671B1 (ko) * 2017-08-21 2019-03-04 충남대학교산학협력단 프로테아좀 억제제를 유효성분으로 함유하는 아토피성 피부질환의 예방, 개선 또는 치료용 조성물
CN111138660B (zh) * 2019-12-20 2020-12-08 浙江大学 一种氟化聚六亚甲基双胍的制备方法
KR20230121863A (ko) 2020-12-17 2023-08-21 아이덱스 래보러토리즈, 인코포레이티드 로키산 홍반열 검출 및 치료
EP4180035A1 (en) 2021-11-15 2023-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568529A (en) * 1896-09-29 Shaving cup
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
DE19500091C1 (de) * 1995-01-04 1996-04-04 Dyckerhoff & Widmann Ag Verfahren zum Erzeugen einer Sollbruchstelle an einem Zugglied für einen Verpreßanker
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
ATE240113T1 (de) * 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
CN1137878C (zh) * 1997-08-04 2004-02-11 大正制药株式会社 芳氧基苯胺衍生物
CN1271342A (zh) 1997-08-15 2000-10-25 F·索西 裂－乳胱氨酸－β－内脂及其类似物的合成
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
ES2352739T3 (es) * 1997-11-21 2011-02-22 Purdue Neuroscience Company 2-aminoacetamidas sustituidas y el uso de las mismas.
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
EP1069111A4 (en) * 1998-03-26 2001-06-06 Shionogi & Co INDOLE DERIVATIVES EXER ANT ANTIVIRAL ACTIVITY
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20040106539A1 (en) 2000-10-12 2004-06-03 Ulrich Schubert Agents for the treatment of viral infections
JP4395549B2 (ja) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬物及び発酵生成物の発見のための海洋放線菌分類群
AU2003223913A1 (en) * 2002-04-05 2003-10-20 Viromics Gmbh Agents for treating less thanigreater thanflaviviridaeless than/igreater than infections
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CA2504933C (en) 2002-11-06 2012-10-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
MX272108B (es) 2003-02-14 2009-11-25 Bayer Healthcare Ag Heterociclos sustituidos.
NZ544858A (en) 2003-06-20 2009-07-31 Univ California Salinosporamides and methods for use thereof
KR20060026052A (ko) 2003-06-20 2006-03-22 니리어스 파마슈티컬즈, 인코퍼레이션 암, 염증 및 감염성 질환의 치료를 위한 [3.2.0]헤테로사이클릭 화합물 및 그 유사체의 사용방법
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
US7579371B2 (en) * 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20060264495A1 (en) * 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
WO2006005551A1 (en) 2004-07-12 2006-01-19 Bayer Cropscience Ag Substituted 2-pyrrolidone derivatives as fungicides and insecticides
KR20070086895A (ko) 2004-12-03 2007-08-27 니리어스 파마슈티컬즈, 인코퍼레이션 〔３．２．０〕헤테로사이클릭 화합물 및 그의 유도체의사용방법
WO2006060609A1 (en) 2004-12-03 2006-06-08 Honeywell International Inc. Gas jet control for inertial measurement unit
MX2007006526A (es) 2004-12-03 2007-09-19 Dana Farber Cancer Inst Inc Composiciones y metodos para tratamiento de enfermedades neoplasicas.
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
WO2006124902A2 (en) * 2005-05-16 2006-11-23 Sloan-Kettering Institute For Cancer Research Synthesis of salinosporamide a and analogues thereof
WO2007021897A1 (en) 2005-08-10 2007-02-22 President And Fellows Of Harvard College Analogs of salinosporamide a
WO2007030662A1 (en) * 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
EP1951226A2 (en) 2005-11-04 2008-08-06 The Regents of the University of California Methods of sensitizing cancer to therapy-induced cytotoxicity
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
BRPI0709474A2 (pt) * 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
US8088923B2 (en) * 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
WO2008137780A2 (en) 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
AU2009241635A1 (en) * 2008-03-07 2009-11-05 Nereus Pharmaceuticals, Inc. Total synthesis of Salinosporamide A and analogs thereof
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
EP2276765A4 (en) 2011-10-19
US20120270919A1 (en) 2012-10-25
CA2723465A1 (en) 2009-11-19
US7910616B2 (en) 2011-03-22
US20110172285A1 (en) 2011-07-14
US8227503B2 (en) 2012-07-24
CN102089312A (zh) 2011-06-08
AU2009246467A1 (en) 2009-11-19
US20090298906A1 (en) 2009-12-03
KR20110011645A (ko) 2011-02-08
IL209046A0 (en) 2011-01-31
ZA201008098B (en) 2011-08-31
US8389564B2 (en) 2013-03-05
CO6290654A2 (es) 2011-06-20
WO2009140287A1 (en) 2009-11-19
MX2010012341A (es) 2010-12-06
JP2011519975A (ja) 2011-07-14
EP2276765A1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
FR17C1011I2 (fr) Inhibiteurs de proteasomes
IL209046A0 (en) Salinosporamide derivatives as proteasome inhibitors
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
BRPI0907061A2 (pt) Derivados de 2-aminoquinolina úteis como inibidores de beta-secretase (base)
BRPI1008749A2 (pt) Derivados de benzodiazepina
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
HRP20150477T1 (xx) Postupci dobivanja derivata kinazolona
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI1013844A2 (pt) derivados de piridina-isoxazol
PT2513105E (pt) Derivados de 2-arilimidazole como inibidores da enzima pde10a
BRPI0912475A2 (pt) compostos como inibidores de quinase
BRPI0909782A2 (pt) Derivados de azetidina
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI1012852A2 (pt) derivados de benzoxazolona como inibidores da sintase de aldoesterona
BRPI0913234A2 (pt) derivados de tiazolilpiperidina
BRPI0922652A2 (pt) Derivados de quinazolinamida
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.